Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06410300 · ClinicalTrials.gov registry record
Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
A clinical trial of Lung Cancer, sponsored by Bo Lu.
- Recruiting
- Registry status
- 125
- Enrollment target
- 3
- Study locations
NCT06410300: Recruiting study of Lung Cancer, sponsored by Bo Lu.
NCT06410300 is a study of Lung Cancer that is actively recruiting participants, run by Bo Lu. The registered enrollment target is 125 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06410300, a study of Lung Cancer, is actively recruiting participants, sponsored by Bo Lu.
- RECRUITING
- Registry status
- 125 participants
- Enrollment target
- 3
- Study locations
Study Summary
The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.
Primary Outcome
To determine clinical cardiopulmonary toxicities from standard RT and immunotherapy per CTCAEv5.0
Conditions Studied
Interventions
- DRUG Immunotherapy
- RADIATION Curative Radiotherapy
Study Locations (3)
Missouri
- University of Missouri - Ellis Fischel Cancer Center - Columbia
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2024-04-19 |
| Est. Completion | 2030-04-19 |
What NCT06410300 shows while recruiting
NCT06410300 is an observational study that tracks outcomes without assigning an intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Immunotherapy is the first listed.
NCT06410300 reports a single indexed study location in Missouri, New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT06410300 about?
NCT06410300 is a clinical study titled "Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy". The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting...
What is the current status of trial NCT06410300?
This trial is currently recruiting. The enrollment target is 125 participants. The study started on 2024-04-19. Estimated completion is 2030-04-19.
What conditions does trial NCT06410300 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT06410300?
The interventions under investigation include: Immunotherapy (DRUG), Curative Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT06410300?
This trial is sponsored by Bo Lu, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06410300 being conducted?
This trial has 3 study locations across Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06410300's enrollment target sits among peer trials
125 165th of 409 higher than 243 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI